SOPHiA GENETICS expands partnership with AstraZeneca for breast cancer research.

SOPHiA GENETICS and AstraZeneca have expanded their partnership to leverage AI Factories for evidence generation and predictive model development in breast cancer treatments. The collaboration will analyze multimodal healthcare data and generate insights for assessing patient prognosis and treatment response. The partnership aims to optimize outcomes for individuals undergoing treatment for breast cancer.

SOPHiA GENETICS (Nasdaq: SOPH) and AstraZeneca (LSE/STO/Nasdaq: AZN) have announced an expansion of their partnership to leverage AI Factories for evidence generation and predictive model development in breast cancer treatments. The collaboration will analyze multimodal healthcare data, including genomics, imaging, and clinical data, to generate insights for assessing patient prognosis and treatment response. The primary goal is to optimize outcomes for individuals undergoing treatment for breast cancer.

The partnership, which is a multi-year collaboration, will utilize SOPHiA GENETICS' AI Factories to analyze complex datasets spanning genomics, imaging, and clinical information. This will enable the generation of real-world evidence in Europe and North America, addressing critical knowledge gaps and enhancing clinical decision-making through deeper insights. AstraZeneca will leverage these AI Factories to optimize breast cancer treatment outcomes by understanding the efficacy drivers and developing bespoke AI-powered predictive models.

Ross Muken, President of SOPHiA GENETICS, stated, "We are proud to deepen our partnership with AstraZeneca through this significant new initiative. Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI." Jorge Reis-Filho, Chief AI and Data Scientist at AstraZeneca, added, "Fine-tuning and augmenting our models with multimodal data – including our own data and the data that will be generated as part of this collaboration – is helping us to generate a more holistic understanding of disease biology and biomarkers to tailor the most effective treatment to patients living with cancer."

This strategic collaboration highlights the growing demand for secure, compliant, and scalable real-world AI applications in healthcare. It also underscores SOPHiA GENETICS' position as a trusted technology partner and reinforces its commitment to advancing global health through federated data analytics and artificial intelligence.

The development of a bespoke predictive model for breast cancer treatment optimization could lead to proprietary clinical decision support tools with commercial applications beyond this single partnership, potentially creating additional revenue opportunities in the future.

References:
1. [https://www.stocktitan.net/news/SOPH/sop-hi-a-genetics-expands-collaboration-with-astra-zeneca-using-ai-huwab81e6lye.html](https://www.stocktitan.net/news/SOPH/sop-hi-a-genetics-expands-collaboration-with-astra-zeneca-using-ai-huwab81e6lye.html)
2. [https://finance.yahoo.com/news/sophia-genetics-expands-collaboration-astrazeneca-104000036.html](https://finance.yahoo.com/news/sophia-genetics-expands-collaboration-astrazeneca-104000036.html)
3. [https://www.prnewswire.co.uk/news-releases/sophia-genetics-expands-collaboration-with-astrazeneca-using-ai-to-improve-breast-cancer-patient-outcomes-302521041.html](https://www.prnewswire.co.uk/news-releases/sophia-genetics-expands-collaboration-with-astrazeneca-using-ai-to-improve-breast-cancer-patient-outcomes-302521041.html)